Table 1.
Pooled hazard ratios of low lean mass on mortality according to cancer type.
| Cancer type | Number of studies | Overall (HR [95% CI]), I2 |
|---|---|---|
| Bile duct (excludes intrahepatic) | 2 | 2.58 [1.82, 3.64], 0% |
| Breast | 3 | 1.69 [0.79, 3.58]; 61% |
| Gastrointestinal | 18 | 1.56 [1.36, 1.78]; 48% |
| Head and neck | 1 | 1.92 [1.19, 3.11]; NA |
| Hematopoietic | 3 | 1.34 [0.51, 3.53]; 73% |
| Liver and intrahepatic bile duct | 17 | 2.22 [1.86, 2.65]; 24%a |
| Lung | 5 | 2.19 [1.28, 3.75]; 60% |
| Ovarian and endometrium | 6 | 1.24 [0.91, 1.70]; 49%b |
| Pancreatic | 8 | 1.63 [1.44, 1.84]; 0% |
| Prostate | 1 | 0.90 [0.54, 1.50]; NA |
| Urinary tract | 12 | 1.88 [1.52, 2.34]; 41% |
| Mixed | 5 | 1.19 [1.03, 1.38]; 61% |
| Overall | 81 | 1.68 [1.55, 1.83]; 63% |
HR, hazard ratio; CI, confidence interval; NA, not applicable.
a
Higashi 2016 performed subgroup analysis, hepatocellular carcinoma subgroup was chosen (appendix p27, ref 58).
b
Rutten 2017 included both lean mass measurements, L3 Skeletal Muscle Index was chosen (appendix p36, ref 145).